SCHEMBL692510

SCHEMBL692510

CCCCCC(C)CC(=O)S

nearest known ligand 0.52

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ACE2 Q9BYF1 1/20 0.52
CA1 P00915 2/20 0.47
GPR84 Q9NQS5 7/20 0.44
FFAR1 O14842 2/20 0.42
MAPT P10636 1/20 0.41
TP53 P04637 1/20 0.41
LCK P06239 1/20 0.41
PPARD Q03181 1/20 0.41
ZDHHC20 Q5W0Z9 1/20 0.41
ZDHHC2 Q9UIJ5 1/20 0.41
CA2 P00918 1/20 0.39
OPRM1 P35372 1/20 0.39
FDPS P14324 1/20 0.39
FFAR4 Q5NUL3 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6720499 0.84
SCHEMBL28480389 0.82 ACE2 (0.55) ACE2CA1GPR84FFAR1MAPT
SCHEMBL13177054 0.80 ACE2 (0.53) ACE2CA1GPR84FFAR1MAPT
SCHEMBL28945792 0.80 ACE2 (0.59) ACE2CA1GPR84FFAR1MAPT
SCHEMBL544052 0.80 GPR84 (0.61) ACE2CA1GPR84FFAR1MAPT
SCHEMBL30882121 0.80 GPR84 (0.61) ACE2CA1GPR84FFAR1MAPT
SCHEMBL28945753 0.80 ACE2 (0.59) ACE2CA1GPR84FFAR1MAPT
SCHEMBL1782208 0.80 ACE2 (0.53) ACE2CA1GPR84FFAR1MAPT
SCHEMBL7497832 0.80 ACE2 (0.53) ACE2CA1GPR84FFAR1MAPT
SCHEMBL21355894 0.79 ACE2 (0.58) ACE2CA1GPR84FFAR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1606248-B1 SULFONIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE SPA (IT) 2012-02-29 EP disclosed
US-7737139-B2 Sulfonic acids, their derivatives and pharmaceutical compositions containing them DOMPE PHA.R.MA S.P.A. (IT) 2010-06-15 US disclosed
US-20060258730-A1 Sulfonic acids, their derivatives and pharmaceutical compositions containing them DOMPE S.P.A. (IT) 2006-11-16 US disclosed
EP-1606248-A2 SULFONIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Dompé S.P.A. (IT) 2005-12-21 EP disclosed
WO-2004080951-A2 SULFONIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE S.P.A. (IT) 2004-09-23 WO disclosed
EP-1457485-A1 Sulfonic acids, their derivatives and pharmaceutical compositions containing them Dompé S.P.A. (IT) 2004-09-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258730-A1 Sulfonic acids, their derivatives and pharmaceutical compositions containing them CCR8, CCR1, CXCR1 ACE2 3538/4885CA1 156/4885GPR84 364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.